Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route

Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates

Peralta-Álvarez MP. et al, (2024), npj Vaccines, 9

Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.

Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Jackson S. et al, (2024), The Lancet Microbe

Demonstrating the utility of the ex vivo murine mycobacterial growth inhibition assay (MGIA) for high-throughput screening of tuberculosis vaccine candidates against multiple Mycobacterium tuberculosis complex strains

Painter H. et al, (2024), Tuberculosis, 102494 - 102494

Determinants of COVID-19 immunisation uptake in a country with high mortality and a low vaccination rate

Aksentijevic D. et al, (2023), Journal of Infection and Public Health, 16, 1322 - 1331

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants

Satti I. et al, (2022), Nature Communications, 13

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model

Yeo T. et al, (2022), Journal of Neuroinflammation, 19

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.

Wilkie M. et al, (2022), Scientific reports, 12

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination

Bitencourt J. et al, (2022), Frontiers in Immunology, 12

Chronovaccination: Harnessing circadian rhythms to optimize immunisation strategies.

Otasowie CO. et al, (2022), Frontiers in immunology, 13

Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.

Burel JG. et al, (2021), Tuberculosis (Edinburgh, Scotland), 131

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.

Sibley L. et al, (2021), Scientific reports, 11

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116

MMR Vaccine Attitude and Uptake Research in the United Kingdom: A Critical Review

Torracinta L. et al, (2021), Vaccines, 9, 402 - 402

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey M. et al, (2021), The Lancet, 397, 881 - 891

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278

Load More

Include forthcoming?